The role of glucocorticoids in increasing cardiovascular risk
Frontiers in Cardiovascular Medicine · 05.07.2023 · 10
DOI: 10.3389/fcvm.2023.1187100 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 05.07.2023. Verfasst von Hai-Wei Deng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Different studies provide conflicting evidence regarding the potential for glucocorticoids (GCs) to increase the risk of cardiovascular diseases. This study performed a systematic review and meta-analysis to determine the correlation between GCs and cardiovascular risk, including major adverse cardiovascular events (MACE), death from any cause, coronary heart disease (CHD), heart failure (HF), and stroke.
Methods
We performed a comprehensive search in PubMed and Embase (from inception to June 1, 2022). Studies that reported relative risk (RR) estimates with 95% confidence intervals (CIs) for the associations of interest were included.
Results
A total of 43 studies with 15,572,512 subjects were included. Patients taking GCs had a higher risk of MACE (RR = 1.27, 95% CI: 1.15–1.40), CHD (RR = 1.25, 95% CI: 1.11–1.41), and HF (RR = 1.92, 95% CI: 1.51–2.45). The MACE risk increased by 10% (95% CI: 6%–15%) for each additional gram of GCs cumulative dose or by 63% (95% CI: 46%–83%) for an additional 10 μg daily dose. The subgroup analysis suggested that not inhaled GCs and current GCs use were associated with increasing MACE risk. Similarly, GCs were linked to an increase in absolute MACE risk of 13.94 (95% CI: 10.29–17.58) cases per 1,000 person-years.
Conclusions
Administration of GCs is possibly related with increased risk for MACE, CHD, and HF but not increased all-cause death or stroke. Furthermore, it seems that the risk of MACE increased with increasing cumulative or daily dose of GCs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
- Key Laboratory on Assisted Circulation Ministry of Health, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
- Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
- The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.
Zitieren
APA
Deng, H. W., Mei, W. Y., Xu, Q., Zhai, Y. S., Lin, X. X., Li, J., Li, T. F., Zheng, Q., Chen, J. S., Ou-Yang, S., Huang, Z. B., & Cheng, Y. J. (2023). The role of glucocorticoids in increasing cardiovascular risk. Frontiers in Cardiovascular Medicine, 10. https://doi.org/10.3389/fcvm.2023.1187100
Vancouver
Deng HW, Mei WY, Xu Q, Zhai YS, Lin XX, Li J, et al. The role of glucocorticoids in increasing cardiovascular risk. Frontiers in Cardiovascular Medicine. 2023;10. doi:10.3389/fcvm.2023.1187100
BibTeX
@article{Deng2023,
author = {Deng, Hai-Wei and Mei, Wei-Yi and Xu, Qing and Zhai, Yuan-Sheng and Lin, Xiao-Xiong and Li, Jie and Li, Teng-Fei and Zheng, Qian and Chen, Jin-Sheng and Ou-Yang, Shun and Huang, Zhi-Bin and Cheng, Yun-Jiu},
title = {The role of glucocorticoids in increasing cardiovascular risk},
journal = {Frontiers in Cardiovascular Medicine},
year = {2023},
volume = {10},
doi = {10.3389/fcvm.2023.1187100}
}
EUVIMED